Thanks Tony, The outline of initial findings by Dr Mondello relates to the first cohort of the Phase II Intrepid2566 trial. Enrolment for the first cohort, however, was completed in May 2011. Its fascinating why the findings are being presented at this stage. Would it really take more than two years to analyse the data?
The blood biomarkers used within the Intrepid trial most likely refer to the work by Banyan Biomarkers. An article in the WSJ discusses the success of Banyan in using biomarkers to track brain injury.
The study at http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219030/ provides great background to the use of biomarkers in severe TBI.
The study talks about how biomarkers might mirror evolving processes in the brain and how changes in biomarker levels can provide 'real-time' complementary information on pathophysiological events that occur following a brain injury.
I've been aware of the presentation for a couple of weeks and have been thinking through the potential implications of the findings. Although of course the trial is double-blind placebo controlled, the findings are of obvious interest in much the same way as a reduction in the mortality rate would portend a therapeutic effect.
Wayne.
NEU Price at posting:
8.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)